C vs KALV · P/E 16, rev $85.22B vs rev $13.7M
Citigroup Inc. (C) versus Kalvista Pharmaceuticals Inc (KALV) — a side-by-side from cached financials, not a winner call.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
C currently screens at market cap $214.73B and trailing P/E 15.5. KALV currently screens at market cap $1.44B.
Not investment advice. Open the C and KALV stock pages for the full models.
Not investment advice.